Battelle Pulmonary Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Battelle believes its electrohydrodynamic (EHD) technology can deliver drugs to the lung to treat asthma, emphysema, cancers of the lung, and other conditions more effectively than existing commercial inhalation systems. Drug companies are interested, as evidenced by the company's deals with Pfizer, the Ross Products division of Abbott, and others. Battelle is partnering EHD and also developing an internally developed inhaled chemotherapy system on its own.
You may also be interested in...
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.